혈액 배양 검사 시장 : 제품 유형별, 기술별, 검사 유형별, 검체 유형별, 시행 방법별, 최종 사용자별, 용도별 - 세계 시장 예측(2026-2032년)

The Blood Culture Test Market is projected to grow by USD 9.23 billion at a CAGR of 7.19% by 2032.

Blood culture testing remains the clinical reference standard for detecting bloodstream infection and confirming sepsis-causing bacteria and fungi. For hospitals, clinical laboratories, diagnostic manufacturers, and antimicrobial stewardship teams, the blood culture test is central to early pathogen identification, targeted antimicrobial therapy, infection control, and patient risk stratification.

The market is being shaped by the global burden of sepsis, which the World Health Organization links to approximately 49 million cases and 11 million deaths annually, and by rising antimicrobial resistance that increases the need for timely, organism-specific diagnosis. Automated blood culture systems, optimized sample collection, rapid organism identification, and susceptibility workflows are increasingly important as health systems seek to reduce time-to-result, avoid unnecessary broad-spectrum antibiotic exposure, and improve outcomes in emergency, intensive care, oncology, neonatal, and transplant settings.

Transformative Shifts in the Blood Culture Testing Landscape

The blood culture test landscape is shifting from conventional culture-only workflows toward integrated diagnostic pathways that combine automated incubation, continuous monitoring, molecular identification, antimicrobial susceptibility testing, and laboratory information system connectivity. This transformation is driven by pressure to shorten time to effective therapy while maintaining the specificity and clinical confidence associated with culture-based diagnosis.

Operationally, laboratories are prioritizing contamination reduction, standardized collection volumes, instrument uptime, and faster downstream identification once a bottle flags positive. Health systems are also aligning blood culture testing with sepsis bundles, antimicrobial stewardship programs, and infection prevention metrics, making diagnostic performance a strategic quality indicator rather than a standalone laboratory function.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating a cumulative impact across the blood culture workflow by improving prediction, prioritization, and interpretation. AI-enabled clinical decision support can help identify patients at elevated sepsis risk, prompt appropriate blood culture collection before antibiotics, and reduce delays in emergency and inpatient care pathways. In the laboratory, machine learning can support signal interpretation, workload forecasting, bottle positivity analytics, contamination monitoring, and quality management.

The greatest near-term value is expected from AI that is embedded into validated clinical workflows rather than used as a replacement for microbiology expertise. When paired with electronic health records, antimicrobial stewardship data, and instrument outputs, AI can help reduce avoidable repeat testing, flag possible contaminants, accelerate escalation for critical results, and support more consistent reporting across high-volume hospital networks.

Key Regional Insights

Asia-Pacific is one of the most dynamic regions for blood culture test adoption, supported by expanding hospital infrastructure, high infectious disease burden, and rising investment in automated microbiology in China, India, Japan, South Korea, and Australia. Demand is reinforced by antimicrobial resistance surveillance needs, the expansion of private laboratory networks in urban centers, and increased focus on sepsis care in tertiary hospitals.

North America is characterized by mature hospital diagnostics, strong sepsis quality initiatives, antimicrobial stewardship mandates, and broad use of automated blood culture platforms. Latin America is advancing through public health modernization and private hospital growth, although access, reimbursement variability, and laboratory infrastructure gaps remain important constraints. Europe benefits from established antimicrobial stewardship frameworks, regional regulatory harmonization for in vitro diagnostics, and strong clinical microbiology standards. The Middle East, particularly high-income Gulf markets, is investing in advanced hospital laboratories and infection control capacity, while Africa continues to face access gaps but represents a critical region for bloodstream infection diagnosis due to infectious disease burden, neonatal sepsis risk, and the need for scalable diagnostic capacity.

Key Group Insights

ASEAN markets are expanding blood culture testing capacity as governments strengthen hospital networks, infectious disease surveillance, and laboratory accreditation, with demand supported by urban tertiary care growth and rising antimicrobial resistance awareness. The GCC is investing in high-throughput automated microbiology systems as part of broader healthcare modernization programs, medical city development, and tertiary care expansion. The European Union continues to influence global standards through in vitro diagnostic regulation, antimicrobial resistance action plans, and coordinated public health surveillance.

BRICS economies represent a major growth base because of large patient populations, rising healthcare expenditure, and urgent antimicrobial resistance priorities across Brazil, Russia, India, China, and South Africa. G7 countries lead in installed diagnostic infrastructure, stewardship integration, laboratory quality systems, and adoption of rapid adjunct technologies. NATO countries show strong demand resilience due to healthcare security priorities, military medicine requirements, and the need for dependable diagnostics during outbreaks, conflict-related care, and cross-border health emergencies.

Key Country Insights

The United States leads through advanced sepsis protocols, large hospital networks, and CDC-driven attention to antimicrobial resistance and healthcare-associated infections. Canada emphasizes standardized laboratory quality and stewardship, while Mexico and Brazil are expanding diagnostic access through mixed public-private healthcare systems. The United Kingdom, Germany, France, Italy, and Spain maintain strong clinical microbiology capabilities, with Germany and France showing notable strength in laboratory automation, antimicrobial stewardship, and hospital-based infectious disease management.

Russia continues to require robust bloodstream infection testing across large regional healthcare systems. China is scaling automated diagnostics rapidly as hospital volumes increase and antimicrobial resistance surveillance becomes more important. India has strong long-term demand driven by sepsis burden, private hospital investment, neonatal and intensive care needs, and the requirement for broader diagnostic access. Japan, Australia, and South Korea are advanced markets with high expectations for quality, automation, and rapid results, supported by mature hospital systems, infection control programs, and strong laboratory governance.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize workflow-integrated innovation that reduces time to organism identification without compromising culture reliability. This includes improving pre-analytical collection quality, optimizing blood volume compliance, integrating rapid identification from positive bottles, strengthening antimicrobial susceptibility workflows, and enabling seamless connectivity with laboratory information systems and antimicrobial stewardship platforms.

Commercial strategy should align with regional readiness. Mature markets need automation, analytics, interoperability, and evidence of clinical utility, while emerging markets need scalable instruments, training, service reliability, and cost-efficient consumables. Vendors and laboratories should also invest in contamination prevention, local validation studies, regulatory readiness, resilient supply chains, and partnerships with hospitals, public health agencies, and stewardship teams.

Research Methodology

This executive summary is based on secondary research from authoritative healthcare, public health, regulatory, and clinical microbiology sources, including global sepsis and antimicrobial resistance evidence from the World Health Organization, national public health agencies, peer-reviewed clinical guidance, and recognized laboratory practice standards. The analysis focuses on verified adoption drivers, workflow trends, regional healthcare dynamics, and technology developments relevant to blood culture testing.

Insights were synthesized through a structured review of disease burden, hospital laboratory modernization, antimicrobial stewardship priorities, diagnostic workflow evolution, regulatory direction, and regional health system capacity. The methodology avoids unverified market sizing claims and emphasizes data-backed directional intelligence suitable for decision-making, and strategic planning.

Conclusion

Blood culture testing remains indispensable in the diagnosis and management of bloodstream infections, particularly as sepsis mortality, antimicrobial resistance, and hospital quality requirements intensify the need for reliable microbiology. The landscape is moving toward faster, more connected, and more automated workflows that preserve the diagnostic authority of culture while accelerating clinical action.

Organizations that combine validated technology, strong laboratory practices, antimicrobial stewardship integration, and regionally tailored execution will be best positioned to support clinical value. The next phase of the blood culture test landscape will be defined by speed, accuracy, workflow intelligence, and equitable access to high-quality bloodstream infection diagnostics.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Blood Culture Test Market, by Product

• 7.1. Consumables
  • 7.1.1. Bottles
  • 7.1.2. Culture Media
  • 7.1.3. Reagent Kits
• 7.2. Instruments
  • 7.2.1. Analyzers
  • 7.2.2. Automation Systems

8. Blood Culture Test Market, by Technology

• 8.1. Conventional
• 8.2. Molecular
  • 8.2.1. Next Generation Sequencing
  • 8.2.2. Polymerase Chain Reaction

9. Blood Culture Test Market, by Test Type

• 9.1. Automated
• 9.2. Manual

10. Blood Culture Test Market, by Sample Type

• 10.1. Plasma
• 10.2. Whole Blood

11. Blood Culture Test Market, by Mode

• 11.1. Central Lab
• 11.2. Point Of Care
  • 11.2.1. Bedside
  • 11.2.2. Portable

12. Blood Culture Test Market, by End User

• 12.1. Ambulatory Care Centers
  • 12.1.1. Independent Clinics
  • 12.1.2. Physician Offices
• 12.2. Blood Banks
• 12.3. Diagnostic Laboratories
  • 12.3.1. Hospital Based Labs
  • 12.3.2. Independent Labs
• 12.4. Hospitals & Clinics
  • 12.4.1. Secondary Hospitals
  • 12.4.2. Tertiary Hospitals

13. Blood Culture Test Market, by Application

• 13.1. Bacterial
  • 13.1.1. Gram Negative
  • 13.1.2. Gram Positive
• 13.2. Fungal
  • 13.2.1. Filamentous Fungi
  • 13.2.2. Yeast
• 13.3. Mycobacterial

14. Blood Culture Test Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Blood Culture Test Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Blood Culture Test Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Abbott Laboratories
• 18.2. Anaerobe Systems, Inc.
• 18.3. Autobio Diagnostics Co., Ltd.
• 18.4. Becton, Dickinson and Company
• 18.5. BINDER GmbH
• 18.6. Biobase Biodusty(Shandong), Co., Ltd.
• 18.7. Biomerieux SA
• 18.8. Bruker Corporation
• 18.9. Danaher Corporation
• 18.10. Devyser AB
• 18.11. Eli Lilly and Company
• 18.12. F. Hoffmann-La Roche Ltd.
• 18.13. HiMedia Laboratories Pvt. Ltd.
• 18.14. Juno Diagnostics, Inc.
• 18.15. Neogen Corporation
• 18.16. Novartis AG
• 18.17. OpGen, Inc.
• 18.18. Scenker Biological Technology Co., Ltd.
• 18.19. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 18.20. Siemens Healthineers AG
• 18.21. T2 Biosystems, Inc.
• 18.22. Terumo Corporation
• 18.23. Thermo Fisher Scientific, Inc.
• 18.24. ZeptoMetrix Corporation